Literature DB >> 15354389

Simple movement sequences better correlate to levodopa plasma levels than complex ones.

S Muhlack1, S Konietzka, D Woitalla, H Przuntek, Th Müller.   

Abstract

Instrumental assessment of movements with a computer based device reflect the clinical response of patients with Parkinson's disease (PD) to dopaminergic stimulation. We investigated associations between levodopa plasma levels, scored motor symptoms of upper limbs and instrumental test outcomes after dopaminergic stimulation. Clinical rating scores, test outcomes for simple and complex motion series significantly improved after oral application of 250 mg of a water soluble, fast absorbed levodopa/benserazide preparation, which induced a significant increase of levodopa in plasma during a two hour interval. There was a significant association between the computed area under the curve-values of levodopa plasma concentrations and test results for simple-, but not for complex movement sequences. Performance of complex motion series additionally ask for concomitant cognitive efforts with consecutive hypothetical involvement of extranigral non dopaminergic systems. In contrast, practice of simple movements is more directly associated to the predominantly dopamine regulated motor system.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15354389     DOI: 10.1007/978-3-7091-0579-5_6

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  2 in total

Review 1.  Tracking extranigral degeneration in animal models of Parkinson's disease: quest for effective therapeutic strategies.

Authors:  Varduhi H Knaryan; Supriti Samantaray; Charlene Le Gal; Swapan K Ray; Naren L Banik
Journal:  J Neurochem       Date:  2011-06-17       Impact factor: 5.372

2.  Impact of Oral Fast Release Amantadine on Movement Performance in Patients with Parkinson's Disease.

Authors:  Siegfried Muhlack; Patricia Müsch; Sandra Konietzka; Dirk Woitalla; Horst Przuntek; Thomas Müller
Journal:  Pharmaceutics       Date:  2010-09-20       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.